ArticleCardiovascular research2017

Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism.

Juan Valle Raleigh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.